I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma
- 1 May 2016
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 46 (3) , 203-214
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and ParagangliomaThe Journal of Clinical Endocrinology & Metabolism, 2009
- Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and ParagangliomaJournal of Clinical Oncology, 2009
- Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of ageEuropean Journal of Cancer, 2008
- The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasmsSurgery, 2004
- CORRESPONDENCEEuropean Journal of Surgical Oncology, 2002
- 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndromeEuropean Journal of Surgical Oncology, 2001
- A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatinEuropean Journal of Cancer, 1995
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastomaEuropean Journal of Cancer, 1995
- Scintigraphic Localization of PheochromocytomaNew England Journal of Medicine, 1981
- Suppression of Thyroid Radioiodine Uptake by Various Doses of Stable IodideNew England Journal of Medicine, 1980